← All trials
NCT04479631
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Mar 31, 2021
- First posted
- Jul 21, 2020
- Last posted
- Dec 3, 2020
- Enrollment
- 16
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Brii BiosciencesLead sponsor
- Government of ChinaStudy director
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.